SCG Cell Therapy Pte Ltd

Jul 07, 2025

SCG Cell Therapy Announces Clearance of Investigational New Drug Application by the China NMPA for SCG101V

May 07, 2025

SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025

Jun 30, 2024

SCG Cell Therapy Announces FDA IND Clearance of SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumors

Jun 07, 2024

EASL Wrap-up Session Highlighted Late-Breaking Clinical Data of First-in-class HBV-specific TCR T Cell Therapy (SCG101) Showing Improved Overall Survival in HBV-related Hepatocellular Carcinoma

May 12, 2024

SCG Cell Therapy Presented New Preclinical Data in an Oral Presentation at ASGCT 2024 Annual Meeting Highlighting Superior Tumor Inhibition of its Immunoswitch Armored HPV-TCR T Cell Therapy (SCG142) against a Broad Range of HPV-associated Cancers

Apr 16, 2024

SCG CELL THERAPY AND A*STAR LAUNCH JOINT LABS WITH COLLABORATION NEARING S$30 MILLION TO ADVANCE iPSC TECHNOLOGY TOWARDS SCALABLE GMP MANUFACTURING OF CELLULAR IMMUNOTHERAPIES